Needham:下调Inozyme Pharma(INZY.US)评级,由买入调整至持有评级,目标价由12.00美元调整至12.00美元。Inozyme Pharma(INZY.US)公司简介:Inozyme Pharma是一家临床阶段的罕见病生物制药公司,致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。该公司致力于开发治疗方法,以解决这些令人痛苦的疾病的根本原因。该公司专注于开发一种...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.